Eversense CGM costs vary widely depending on insurance coverage, but the out-of-pocket price without insurance for the full system runs into thousands of dollars per year. Unlike disposable sensor-based CGMs that you apply yourself, Eversense uses an implantable sensor placed under the skin by a healthcare provider, which means the cost structure is fundamentally different: you’re paying for the sensor hardware, a reusable smart transmitter, and medical procedures for insertion and removal. That layered pricing makes the question of “how much does it cost” harder to answer with a single number than it is for most other glucose monitors.
Why Eversense Pricing Works Differently
Most continuous glucose monitors use disposable sensors that you stick onto your skin every week or two. Eversense takes a completely different approach. The sensor is a small, fluorescence-based implant placed just beneath the skin of the upper arm during a brief in-office procedure. A removable smart transmitter worn over the implant site picks up glucose readings and sends them to a mobile app.1International Journal of Diabetes and Technology. The Historical Evolution of Continuous Glucose Monitoring – The Story of 25 Years – Section: CGMS WITH IMPLANTABLE SENSORS That means your total cost has three components: the sensor itself, the transmitter, and the healthcare provider’s fees for putting the sensor in and eventually taking it out.
The current version, Eversense E3, was approved by the FDA in 2022 for up to six months of continuous use. That means you need only two sensor insertions per year rather than swapping a disposable sensor every one to two weeks. Fewer replacements sounds like it should be cheaper, but each insertion involves a minor procedure performed in a doctor’s office, and the sensor hardware carries a substantial price tag. The transmitter is reusable across sensor cycles, so you typically buy it once and then charge it between uses.
Approximate Costs Without Insurance
Without any insurance coverage, the cost of the Eversense system for a full year generally falls in the range of several thousand dollars. The sensor is the most expensive individual component. Because it is a long-wear implantable device with specialized fluorescence technology, each sensor carries a higher unit price than a box of disposable adhesive sensors. You need two sensors per year with the E3 version. The transmitter is a one-time purchase that you keep from cycle to cycle, though it will eventually need replacement after a few years of use.
On top of the hardware, you have to factor in the cost of the insertion and removal procedures. These are performed in a healthcare provider’s office and typically billed as outpatient procedures. The insertion itself is a quick process, usually done under local anesthesia, but it still generates a medical bill. Removal at the end of the sensor’s life adds another visit. If your provider bundles insertion and removal into a single visit when swapping sensors, that can reduce the total number of office appointments to two per year.
Adding everything up, the total annual cost without insurance can be broadly comparable to or somewhat higher than what you’d pay out of pocket for other CGM systems on an annual basis. The sticker price looks large when you see it as a lump sum for each sensor cycle, whereas disposable CGM costs get spread across dozens of smaller purchases throughout the year. The psychological experience of paying is different even when the annual totals are in a similar ballpark.
What Insurance Typically Covers
If you have insurance, Eversense costs drop considerably for most people. Commercial health plans increasingly cover continuous glucose monitoring devices, and Eversense is included in the formularies of many major insurers. Coverage typically applies to the sensor, the transmitter, and the insertion and removal procedures, though your out-of-pocket share depends on your plan’s specifics: your deductible, coinsurance percentage, copay structure, and whether the device is classified under your pharmacy benefit or durable medical equipment benefit.
Medicare covers CGM for beneficiaries with diabetes who meet certain criteria, which generally includes using insulin or having a history of problematic blood sugar control. Under Medicare, Eversense falls under the durable medical equipment category. Medicaid coverage varies by state, but many state Medicaid programs now cover CGM devices. If you’re on Medicaid, checking with your state’s specific program is worth the effort, since coverage details and prior authorization requirements differ significantly from one state to another.
One thing that catches people off guard is that the insertion and removal procedures may be billed separately from the device itself. The sensor and transmitter might go through your pharmacy benefit or DME benefit, while the provider’s procedure is billed as a medical claim. That means you could face cost-sharing under two different parts of your plan. If your plan has a separate deductible for medical services versus DME, you might need to satisfy both before your coverage kicks in fully.
Senseonics Patient Support Programs
Senseonics, the company behind Eversense, has historically offered patient support programs aimed at reducing out-of-pocket costs. These programs have included copay assistance cards for commercially insured patients and bridge programs for people transitioning between insurance coverage. The specifics of these programs change over time, so checking directly with Senseonics or your prescribing provider for current offerings is the most reliable approach.
Some providers who perform Eversense insertions also have financial counselors or patient navigators who can help you understand your expected costs before committing to the device. Because the insertion is an in-office procedure, the provider’s billing department can often run a benefits check and give you an estimate of what your plan will cover and what you’ll owe. This is worth doing before your first insertion, since the cost surprise tends to be largest for new users who haven’t seen how their specific plan handles the device.
How the Cost Compares to Other CGM Systems
Comparing Eversense costs to those of other CGMs is tricky because the cost structures are so different. Disposable-sensor systems like Dexcom G7 or FreeStyle Libre involve ongoing purchases of sensor patches, usually every ten to fourteen days. You’re buying consumables regularly, but each individual purchase is relatively small. Eversense front-loads cost into the sensor and procedure, then you have months of monitoring with no recurring sensor purchases.
On an annual basis, the total cost of ownership for Eversense and disposable CGMs can wind up surprisingly close for some patients, while for others the gap is meaningful. The variables that swing the comparison include your insurance plan’s specific coverage terms for each device, whether your provider charges above or below average for the insertion procedure, and whether you value the convenience of fewer device changes enough to accept a different payment pattern. For a person whose insurance covers both options equally, the annual net cost may be similar. For someone paying entirely out of pocket, the upfront lump sums for Eversense can feel more burdensome even if the yearly total is comparable.
One area where Eversense has a structural cost advantage is in reduced waste and fewer supply orders. With disposable sensors, missed shipments or supply chain hiccups can leave gaps in monitoring. Eversense’s six-month sensor cycle means fewer transactions with your supplier and less risk of running out of sensors unexpectedly.
The Economic Case for CGM in General
Regardless of which CGM system you choose, the broader economic picture favors continuous monitoring for people who need it. Research has consistently found that CGM use is associated with fewer diabetes-related complications and hospitalizations, which translates to lower overall healthcare spending even after accounting for the cost of the device itself.2PubMed. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus
A large study of Medicaid beneficiaries with type 2 diabetes found that starting CGM was linked to meaningful reductions in both emergency department visits and hospital admissions. Among patients on multiple daily insulin injections, hospitalization rates dropped from about 3.25 to 2.29 events per patient-year, and ED visit rates fell as well. Similar reductions appeared in patients on basal insulin therapy.3PubMed Central. Impact of continuous glucose monitoring on emergency department visits and all-cause hospitalization rates among Medicaid beneficiaries with type 2 diabetes treated with multiple daily insulin or basal insulin therapy Fewer ER trips and hospital stays add up to substantial savings, often exceeding the cost of the CGM device over time. This is one reason insurers have become increasingly willing to cover CGM: it tends to pay for itself by preventing expensive acute events downstream.
This economic argument is worth keeping in mind if you’re debating whether the price of Eversense (or any CGM) is justified. The device cost is real and sometimes significant, but it exists in the context of a condition where poor glucose control leads to complications that are far more expensive to treat.
Hidden Costs and Practical Considerations
Beyond the sticker price, a few practical cost factors are easy to overlook when budgeting for Eversense. The adhesive patches used to hold the transmitter in place over the implant site are a recurring consumable. They’re inexpensive compared to the sensor, but they do add a small ongoing cost. Some users also find they need skin-prep products or adhesive removers to keep the transmitter site comfortable, which adds a few more dollars per month.
The insertion and removal appointments themselves carry indirect costs. You need to get to a provider who performs the procedure, which may or may not be your regular endocrinologist. In areas where few providers offer Eversense insertion, travel time and distance can become a factor. The procedure is quick and straightforward, but it’s still a medical appointment you need to schedule and attend, which means time away from work or other obligations twice a year.
If you’re switching to Eversense from a disposable CGM system, there can be a brief gap in monitoring during the transition. The sensor needs a short warm-up period after insertion before it begins delivering accurate readings. Planning for that overlap, or accepting a short gap, is part of the practical calculus.
Who Eversense Makes the Most Financial Sense For
Eversense tends to be the most cost-effective choice for people who plan to use CGM continuously for years and who find disposable sensor changes burdensome. If you have good insurance coverage that treats Eversense similarly to other CGMs, the financial difference may be negligible while the convenience difference is substantial. Going six months between sensor changes instead of swapping sensors every week or two is a genuine quality-of-life improvement for many users.
People with skin sensitivity or adhesive allergies sometimes find Eversense easier to tolerate, since the transmitter’s adhesive footprint is smaller and the sensor itself sits beneath the skin rather than being held on by a large patch. If adhesive reactions have been driving up your costs with disposable CGMs through wasted sensors, skin treatments, and barrier products, that’s a hidden savings worth considering.
On the other hand, if you’re someone who uses CGM intermittently rather than continuously, or if you’re testing CGM for the first time and aren’t sure you want to commit, starting with a disposable system makes more financial sense. The commitment with Eversense is inherently longer: once the sensor is implanted, you’re in for the full cycle. There’s no equivalent of just not opening the next box of sensors if you decide to take a break.
Eversense E3 and Accuracy Improvements
One factor that indirectly affects the value proposition is accuracy. The Eversense E3 sensor has a mean absolute relative difference of 8.5%, which is a measure of how closely its glucose readings match a lab reference.1International Journal of Diabetes and Technology. The Historical Evolution of Continuous Glucose Monitoring – The Story of 25 Years – Section: CGMS WITH IMPLANTABLE SENSORS Lower numbers indicate better accuracy, and this figure is competitive with the best disposable CGMs on the market. For a device that stays in your body for half a year, maintaining that level of accuracy over the full wear period is a meaningful engineering achievement.
Accuracy matters for cost in a roundabout way. A less accurate sensor leads to more fingerstick confirmations, more second-guessing of readings, and potentially more glucose test strip purchases. It can also lead to less confident insulin dosing decisions, which in turn affects glucose control and the downstream costs associated with poor management. The E3’s accuracy is good enough that most users rely on it as their primary glucose data source without routine fingerstick backup, which keeps the ancillary costs low.
The system also features on-body vibration alerts that notify you of glucose highs and lows even when your phone isn’t nearby. This is the only implantable CGM that provides haptic alerts directly through the transmitter worn on the skin, which can catch dangerous glucose swings while you’re sleeping or driving. Preventing a single severe hypoglycemic episode that results in an ER visit could easily offset months of device costs, making the alert system a quiet but real financial safeguard.
Navigating Prior Authorization
Many insurance plans require prior authorization before they’ll cover Eversense. This means your doctor submits documentation showing that CGM is medically necessary for your diabetes management. The process can take anywhere from a few days to several weeks, and denials aren’t uncommon on the first attempt. If your initial authorization is denied, an appeal with additional clinical documentation from your endocrinologist often succeeds.
The prior authorization process is free but not effortless. It requires coordination between you, your prescribing provider, and sometimes the DME supplier. Some Eversense providers have staff dedicated to handling insurance paperwork, which can speed things along. If your provider doesn’t have that support, being proactive about following up with your insurance company can prevent the process from stalling. The time investment in getting authorization right is worth it: the difference between covered and uncovered Eversense can easily be thousands of dollars per year.
Keep in mind that authorization for the device and authorization for the insertion procedure may be handled separately by your plan. Getting the sensor approved doesn’t automatically mean the procedure is pre-approved, and vice versa. Confirming both before your scheduled insertion date prevents unpleasant billing surprises after the fact.